Intranasal Monoclonal Antibody “Molecular Shield” as a Novel Preventive Strategy for Seasonal Allergic Rhinitis
Abstract
Seasonal allergic rhinitis (SAR) significantly impairs quality of life, with rising prevalence due to environmental and climatic factors. Current therapies—antihistamines, corticosteroids, and allergen immunotherapy—are limited by delayed onset, side effects, or adherence challenges. A novel approach employing intranasally delivered monoclonal antibodies (mAbs) to create a local “molecular shield” against inhaled allergens has recently demonstrated efficacy in animal models. This abstract aims to highlight the potential of intranasal mAbs as a preventive intervention for SAR.
Fields of Study & Subjects
Allergic Rhinitis and Sensitization
Food Allergy and Anaphylaxis Research
Asthma and respiratory diseases
Publication details
- Journal / source
- World Allergy Organization Journal
- Volume
- 19
- Issue
- 2
- Pages
- 101297–101297
- Publication date
- 1 February 2026
- Language
- EN